Publications & Presentations

The publications and presentations listed below serve to demonstrate the experience of the senior management of HSC Preclinical Services in the drug discovery and development industry.

Publications

1)  Murphy, T. M., J. Deitz, P. Petersen, S. Mikels, W. Weiss. 2000. Therapeutic Efficacy of GAR-936, a Novel Glycylcycline, in a Rat Model of Experimental Endocarditis, Antimicrob. Agents and Chemother. 44(11):p3022-3027.

2)  Singh, M., P. Petersen, W. Weiss, F. Kong & M. Greenstein. 2000. Saccharomicins, novel heptadecaglycoside antibiotics produced by Saccharothrix espanaensis : Antibacterial and mechanistic activities. Antimicrob. Agents Chemother. 44: p2154-2159.

3)  Edelstein, P., W. Weiss & M. Edelstein. 2003. In vitro activity of Tigecycline (GAR-936) against Legionella pneumophilia, its pharmacokinetics in guinea pigs and use to treat guinea pigs with L. pneumophilia pneumonia. Antimicrob. Agents Chemother. 47(2):533-540.

4)  Weiss, W., T. Murphy, M. Lynch, J. Frye, A. Buklan, B. Gray, E. Lenoy, S. Mitelman, J. O’Connell, S. Quartucccio & C. Huntley. 2003. Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J Med. Primatology. 32(2):82-88.

5)  Weiss, W., E. Lenoy, T. Murphy, L. Tardio, P. Burgio, S. Projan, O. Schneewind & L. Alksne. 2004. The effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection. J Antimicrob. Chemother. 53:480-486.

6)  Venkatesan, A., A. Agarwal, T. Abe, H. Ushirogochi, I. Yamamura, T. Kumagai, P. Petersen, W. Weiss, E. Lenoy, Y. Yang, D. Shlaes, J. Ryan & T. Mansour. 2004. Novel imidazole substituted 6-methylidene-penems as broad-spectrum b-lactamase inhibitors. Bioorg. Med. Chem. 12:5807-5817.

7)  Weiss, W., T. Murphy, E. Lenoy & M. Young. 2004.  In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental models of infection. Antimicrob. Agents Chemother. 48(5):1708-1712.

8)  Geneive E. Henry, Smita Raithore, Yanjun Zhang, Bolleddula Jayaprakasam, Muraleedharan G. Nair, David Heber, Navindra P. Seeram. Acylphloroglucinol derivatives from Hypericum prolificum. Journal of Natural Products, 69, 1645-1648, 2006.

9)  Yun Wang, Barbara Christian, Ernestine Mitchell, Bolleddula Jayaprakasam, Muraleedharan G. Nair, Jeffery M. Peters, Julia Busik, L. Karl Olson and Donald B. Jump.  Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. Journal of Lipid Research, 47, 2028-2041, 2006.

10) Weiss, W., P. Petersen, T. Murphy, L. Tardio, Y. Yang, P. Bradford, A. Venkatesan, T. Abe, T. Isoda, A. Mihira, H. Ushirogochi, T. Takasake, S. Projan, J. O’Connell & T. Mansour. 2004. In vitro and in vivo activity of novel 6-methylidene penems as b-lactamase inhibitors. Antimicrob. Agents Chemother. 48(12):4589-4596.

11) Gonzales XF, Deshmukh A, Pulse M, Johnson K, Jones HP. 2008. Stress-induced differences in primary and secondary resistance against bacterial sepsis corresponds with diverse corticotropin releasing hormone receptor expression by pulmonary CD11c+ MHC II+ and CD11c- MHC II+ APCs.  Brain Behav Immun. May;22(4):552-64.

12) Kim IH, Combrink KD, Ma Z, Chapo K, Yan D, Renick P, Morris TW, Pulse M, Simecka JW, and Ding CZ. 2007.  Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins..  Bioorg Med Chem Lett. Mar 1;17(5):1181-4

13) Bao, D., T. Truong, P. Renick, M. Pulse & W. Weiss. 2008. Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 46:723-727.

14) Endimiani, A., K. Hujer, A. Hujer, M. Pulse, W. Weiss & R. Bonomo. 2011. Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-Producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55(1):82-85.

15) Olson, P., L. Kuechenmeister, K. Anderson, S. Daily, K. Beenken, C. Roux, M. Renierre, T. Lewis, W. Weiss, M. Pulse, P. Nguyen, J. Simecka, J. Morrison, K. Sayood, O. Asojo, M. Smeltzer, P. Dunman. 2011. Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular turnover, exhibit antimicrobial activity and attenuate pathogenesis. PLos Pathogens. Vol. 7 (2):e1001287.

16) Parsons, J., M. Kukula, P. Jackson, M. Pulse, J. Simecka, D. Valtierra, W. Weiss, N. Kaplan, C. Rock. 2013. Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252. Antimicrob. Agents Chemother. In press.

17) Weiss, W., M. Pulse, R. Vickers. 2014. In Vivo assessment of SMT19969 in a hamster model of Clostridium difficile Antimicrob. Agents Chemother. 58(10):5714-5718.

18) Hilliard, J., Vivekananda Datta, Christine Tkaczyk, Melissa Hamilton, Agnieszka Sadowska, Omari Jones-Nelson, Terrence O’Day, William J. Weiss, Szabolcs Szarka, Vien Nguyen, Laszlo Prokai, JoAnn Suzich, C. Kendall Stover, and Bret R. Sellman. 2015. Anti-alpha toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrob. Agents Chemother. 59(1):299-309.

19) Diep, B., J. Hilliard, V. Le Minh, C. Tkaczyk, H. Le, V.Tran, R. Rao, E. Dip, E. Pereira-Franchi, P. Cha, S. Jacobson, R. Broome, L. Cheng, W. Weiss, L. Prokai, V. Nguyen, K.Stover, B. Sellman. 2017. Targeting Alpha Toxin to Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia. Antimicrob. Agents Chemother. (in press).

20) Marshall, S., A. Hujer, L. Rojas, K. Papp-Wallace, R. Humphries, B. Spellberg, K. Hujer, E. Marshall, S. Rudin, F. Perez, B. Wilson, R. Wasserman, L. Chikowski, D. Paterson, A. Vila, D. van Duin, B. Kreiswirth, H. Chambers, V. Fowler, M. Jacobs, M. Pulse, W. Weiss, R. Bonomo. 2017. A new opportunity”: Can ceftazidime/avibactam and aztreonam overcome ß-lactam resistance conferred by metallo-ß-lactamases in Enterobacteriaceae. Antimicrob. Agents Chemother. (in press).

21) Grossman, T., C. Fyfe, W. O’Brien, M. Hackel, M. Minyard, K. Waites, J. Dubois, T. Murphy, A. Slee, W. Weiss, J. Sutcliffe. 2017. The Fluorocycline TP-271 is Potent Against Complicated Community-Acquired Bacterial Pneumonia (CABP) Pathogens, mSphere (in press).

22) C. Burdet S. Sayah-Jeanne T. Thuy Nguyen, C. Miossec, N. Saint-Lu, M. Pulse, W. Weiss, A. Andremont, F. Mentré, J. de Gunzburg. 2017. Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis. Antimicrob Agent Chemother. (in press).

23) Weiss, W., Pulse, M., Nguyen, P., Peterson, K.,Silva, J., Simecka, J., Valtierra, D., Sabet, M., Griffith, D. 2018. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis. Antimicrob. Agents Chemother. posted online 16 October 2017, doi:10.1128/AAC.01439-17.

24) Burdet, C., Sayah, S., Nguyen, T., Hugon, P., Sablier-Gallis, F., Saint-Lu, N., Corbel, T., Ferreira, S., Pulse, M., Weiss, W., Andremont, A., Mentre, F., Gunzburg, J. 2018. Antibiotic-induced dysbiosis predicts mortality in an animal model of Clostridium difficile infection. Accepted manuscript posted online 30 July 2018 doi:10.1128/AAC.00925-18.

25) Kers, J., A. DeFusco, J. Park, J. Xu, M. Pulse, W. Weiss, M. Handfield. 2018. OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections. PLoS ONE 13(6): e0197467. https://doi.org/10.1371/ journal.pone.0197467

26) Kers, J., R. Sharp, A. Defusco, J. Park, J. Xu, M. Pulse, W. Weiss, M. Handfield. 2018. Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection. Frontiers Microb. 9 (415) 22-35.

27) Pulse, M., W. Weiss, J. Kers, A. DeFusco, J. Park, M. Hanfield. 2019. Pharmacological, Toxicological and Dose-Range Assessment of OG716, a Novel Lantibiotic for the Treatment of Clostridium difficile Associated Infection (CDI). Antimicrob. Agents Chemother. Accepted for pub;lication.

28) Weiss, W., M. Pulse, P. Nguyen, E. Growcott. 2019. In vivo efficacy of novel monobactam LYS228 in murine models of carbapenemase-producing Klebsiella pneumoniae infection. Antimicrob. Agents Chemother. Accepted for publication

29) Heidebrecht, H., Weiss WJ, Pulse M, Lange A, Gisch K, Kliem H, Mann S, Pfaffl MW Kulozik U, von Eichel-Streiber. 2019. Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model. Toxins 11(2).

30) Wu, Zhi-Chen; N. Isley, A. Okano, W. Weiss, D. Boger, Dale. 2019. C1-CBP-Vancomycin: Impact of a Vancomycin C-terminus Trimethylammonium Cation on Pharmacological Properties and Insights into its Newly Introduced Mechanism of Action. J Organic Chem. 

31) Saint-Lu, N., C. Burdet, F. Sablier-Gallis, T. Corbel, A. Nevière, S. Sayah-Jeanne, M. Pulse, W. Weiss, S. Ferreira, A. Andremont, F. Mentre J. de Gunzburg. 2019. DAV131A protects hamsters from lethal Clostridioides difficile infection induced by fluoroquinolones. Antimicrob Agents Chemother. 

32) Liu, Bin; Trout, Robert; Chu, Guo-Hua; McGarry, Daniel; Jackson, Randy; Hamrick, Jodie; Daigle, Denis; Cusick, Susan; Pozzi, Cecilia; De Luca, Filomena; Benvenuti, Manuela; Mangani, Stefano; Docquier, Jean-Denis; Weiss, William; Pevear, Daniel; Xerri, Luigi; Burns, Christopher. 2019. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-Lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. Journal of Medicinal Chemistry Manuscript ID: jm-2019-01518j.R1

33) James M. Byrne, Ursula Waack, Edward A. Weinstein, Abhay Joshi, Simone M. Shurland, Dmitri Iarikov, Jürgen B. Bulitta, Binh An Diep, Tina Guina, William W. Hope, Matthew B. Lawrenz, Alexander J. Lepak, Brian M. Luna, Lynn Miesel, Andrew J. Phipps, Thomas J. Walsh, William Weiss, Thushi Amini, John J.Farley. 2020. FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. Antimicrob Agents Chemother Dec 2020, 65 (1) e01983-20; DOI: 10.1128/AAC.01983-20.

34) Chiari, E., W. Weiss, M. Simon, S. Kiessig, M. Pulse, S. Brown, H. Gerding, M. Mandago, K. Gisch, C. von Eichel-Streiber. 2021. Oral Immunotherapy with Human Secretory IgA Improves Survival in the Hamster Model of Clostridioides difficile Infection. J Infect Diseases. 15February2021. https://doi.org/10.1093/infdis/jiab087.

35) Nhu Nguyen, Emmanuelle Gras, Nguyen Tran, Nhi Nguyen, Hanh Lam, William Weiss, Thien M Doan, and Binh Diep. 2021. Pseudomonas aeruginosa Ventilator-Associated Pneumonia Rabbit Model for Preclinical Drug Development. [AAC02724-20R1].

36) Chatwin, C., J. Hamrick, R. Trout, C. Myers S. Cusick, W. Weiss, M. Pulse, L. Xerri, C. Burns, G. Moeck, D. Daigle, K. John, T. Uehara, D. Pevear. 2021. Microbiological characterization of VNRX-5236: a broad spectrum β-lactamase inhibitor for rescue of the orally bioavailable cephalosporin ceftibuten as a carbapenem-sparing agent against strains of Enterobacterales expressing extended spectrum b-lactamases and serine carbapenemases. Antimicrob Agents Chemother doi:10.1128/AAC.00552-21.

37) Trout RE, Zulli A, Mesaros E, Jackson RW, Boyd S, Liu B, Hamrick J, Daigle D, Chatwin CL, John K, McLaughlin L, Cusick SM, Weiss WJ, Pulse ME, Pevear DC, Moeck G, Xerri L, Burns CJ. 2021. Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes. J Med Chem. PMID: 34191513.

38) Howard, G., N. Bender, P. Khare, B. Lopez-Gutierrez, V. Nyasembe, W. J. Weiss, J. W. Simecka, T. Hamerly, H. Mao, R. R. Dinglasan. 2021. Immunopotentiation by a lymph node-targeted malaria transmission-blocking nanovaccine. Frontiers Immunology.

39) Ma, Z., R. Ebright, V. Molodtsov, G. Robertson, W. Weiss, M. Pulse, P. Nguyen, L. Duncan, T. Doyle, A. Lynch. Design, Synthesis and Characterization of TNP-2198, a Dual-Acting Rifamycin-Nitroimidazole Conjugate Intended for the Treatment of Microaerophilic and Anaerobic Infections. 2022. J Med Chem. Feb 17. doi: 10.1021/acs.jmedchem.1c02045

Abstracts and Presentations

1)  Murphy, T., E. Lenoy, M. Young & W. Weiss. 2002. In vivo efficacy of AC98-6446, a novel glycopeptide, in experimental models of infection. Abstract # F356, 42nd ICAAC, San Diego, CA.

2)  Edelstein, P., W. Weiss & M. Edelstein. 2002. Tigecycline (GAR-936) Activity vs. LegionellaIn Vitro, and in a Cell and Animal Model of Legionnaires’ Disease. Abstract#E-1138. , 42nd ICAAC, San Diego, CA.

3)  Weiss, W., E. Lenoy, T. Murphy, L. Tardio, P. Burgio, S. Projan, O. Schneewind & L. Alksne. 2003. The effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection. Abstract#480. 43rd ICAAC, Chicago, IL.

4)  T. Abe, H. Ushirogochi, I. Yamamura, T. Kumangi, T. Mansour, A. Venkatesan, A. Agarwal, P. Petersen, E. Lenoy, W. Weiss, Y. Yang & D. Shlaes. 2003. Novel penems bearing a methylidine linkage as a broad spectrum b-lactamase inhibitor. Abstract#873. 43rd ICAAC, Chicago, IL.

5)  Venkatesan, A., T. Mansour, O. Dos Santos, A. Agarwal, P. Petersen, W. Weiss, Y. Yang, D. Shlaes, T. Abe, H. Ushirogochi, I Yamamura & T. Kumagai. 2004. Novel penems bearing a bicyclic heterocycle on methylidene linkage as broad spectrum b-lactamase inhibitors and their mechanism of action. Abstract#F-320. 44th ICAAC, Washington, DC.

6)  Bao, D., P.  Renick, M. Pulse, T. Truong, T. Morris & W. Weiss. 2005. In vivo evaluation of antimicrobial agents against device related Staphylococcus aureus infections in a mouse subcutaneous implant model. Drug Discovery Technology & Development (IBC), Boston, MA.

7)  Miller, G., D. Beeman, E. Roche, R. England, W. Weiss & T. Morris. 2005. Enhanced drip flow reactors for pharmacodynamic profiling of antibacterials against staphylococcal biofilms. Abstract#1842. 45th ICAAC, Washington, DC.

8)  Renick, P., M. Pulse, E. Roche, D. Beeman, W. Weiss & T. Morris. 2005. Antibacterial Efficacy and Resistance in a Mouse Model of Device Infections Caused by Staphylococcal Biofilms. USC Microbial Biofilm Symposium, Los Angeles, CA.

9)  Pulse, M., P. Renick, W. Weiss, D. Beeman, T. Truong, D. Bao & T. Morris. 2005. A Rat Central Venous Catheter (CVC) Model of Intravascular Device Infections Caused by Staphylococcal Biofilms. USC Microbial Biofilm Symposium, Los Angeles, CA.

10) XF Gonzales, A Deshmukh, S Johnson, ME Pulse, and HP Jones. 2007.  Acute Stress Impairs Acquired Immune Protection against Streptococcus pneumoniae Despite Delayed Lethality During Initial Infection.  ASM-General Meeting.

11) A Odeh, M Pulse, and JW Simecka. 2007.  Alpha-toxin is Important for Biofilm Formation by Staphylococcus aureus. U.N.T.H.S.C., Research Appreciation Day, April.

12) ME Pulse and ME Hart.  2003. The Role of Serin e Protease-Like F (Spl ) on Alpha-Toxin Expression within Staphylococcus aureus. (poster presentation). U.N.T.H.S.C., Research Appreciation Day.

13) Odeh, A., M. Pulse, P. Renick, W. Weiss, T. Morris, K. Overheim & J. Simecka. 2007. The impact of alpha toxin on in vitro and in vivo biofilm development in Staphylococcus aureus. Poster#B-207. 107th ASM General Meeting, Toronto, Canada

14) Pulse, M., P. Nguyen, P. Renick, W. Weiss, T. Morris & J. Simecka. 2007. Host responses impact antibiotic efficacy and resistance in a mouse subcutaneous device infection model caused by Staphylococcus aureus biofilms. Poster#B-304. 107th ASM General Meeting, Toronto, Canada

15) Renick, P., T. Morris, P. Nguyen, M. Pulse & W. J. Weiss. 2007. Efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, in rodent models of bacterial infection. Abstract#F2105. 47th ICAAC, Chicago, IL.

16) Weiss, W.J., D. Bao, G. Miller, T. Morris, P. Nguyen, M. Pulse, P. Renick & T. Truong.  2007. Pharmacokinetic and pharmacodynamic studies with CBR-2092, a novel rifamycin-quinolone hybrid antibiotic. Abstract#F2106. 47th ICAAC, Chicago, IL.

17) Xiong, Y., W. Weiss, T. Doyle, G. Abdelsayed & A. Bayer. 2007. Efficacy of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic, and Vancomycin in Experimental Methicillin-Resistant Staphylococcus aureus (MRSA) Infective Endocarditis (IE). Abstract#F2107. 47th ICAAC, Chicago, IL.

18) Xiong, Y., W. Weiss, T. Doyle, G. Abdelsayed & A. Bayer. 2007. Comparative Efficacy of CBR-2092 and Conventional Rifampin+Quinolone Combinations in Experimental Infective Endocarditis (IE) Caused by a Quinolone-Resistant MRSA (QRMRSA). Abstract#F2108. 47th ICAAC, Chicago, IL.

19)  Weiss, W., B. Hafkin, N. Kaplan, M. Pulse, P. Nguyen. 2008. Efficacy of AFN-1252 and vancomycin in the mouse subcutaneous abscess model with a methicillin resistant S. aureus. Abstract F1-329. 48th ICAAC, Washington, DC.

20) Pulse, M. E., P. Nguyen, W. J. Weiss, J. W. Simecka. 2009. Alpha-toxin expression and host immunity impact disease severity in a mouse subcutaneous abscess model infected with Staphylococcus aureus. Abstract 09-GM-A-3900. ASM General Meeting, Philadelphia, PA.

21) Pulse, M.E., W. J. Weiss, P. Nguyen, J. Pierce, J. Simecka, R. Scott. 2009. Efficacy of PMX30063 in experimental staphylococcal skin and skin structure infection models. Abstract F1-2013. 49th ICAAC, San Francisco, CA.

22) Weiss, W. J., M. E. Pulse, A. Endiminai, K. Hujer, A. Hujer, R. Bonomo. 2009. Efficacy of NXL104 in combination with ceftazidime in murine infection models. Abstract B-1339. 49th ICAAC, San Francisco, CA.

23) Weiss, W. J., M. E. Pulse, P. Nguyen, J. Pierce, J. Simecka, M. Page. 2009. Efficacy of BAL30072 in experimental respiratory tract infections. Abstract F1-1485. 49th ICAAC, San Francisco, CA.

24) Renick, P. J., E. Roche, S. Tetens, D. Telgenhoff, E. Daniels, L. Seal, D. Carson. 2009. A porcine model of MRSA infection in full thickness wounds with reproducible delayed healing. SAWC/WHS meeting, Dallas, TX.

25) Renick, P.J., E. Roche. 2009. A murine model for biofilm infections in partial thickness wounds. SAWC/WHS meeting, Dallas, TX.

26) Pulse, M., P. Nguyen, J. Pierce, P. Renick, W. Weiss, J. Simecka. 2010. Efficacy of topical and systemic antibiotics in a mouse superficial skin infection model with Staphylococcus aureus. Abstract A-2969. ASM General Meeting, San Diego, CA.

27) Landersdorfer, C., W. J. Weiss, A. Forrest, S. Bhavani, M. Pulse, L. Xerri, P. Ambrose. 2010. Razupenem pharmacokinetics-pharmacodynamics, against enterobacteriaceae and S. aureus in a murine thigh and lung infection model. Abstract. 50th ICAAC, Boston, MA.

28) Weiss, W. J., M. E. Pulse, P. Renick, P. Nguyen, J. Simecka, J. Sutcliffe. 2010. Efficacy of fluorocycline TP-434 in the neutropenic thigh infection model is predicted by AUC/MIC. Abstract. 50th ICAAC, Boston, MA.

29) Weiss, W. J., M. E. Pulse, P. Renick, J. Simecka, W. Stubbings, H. Labischinski. 2010. Pharmacokinetics-pharmacodynamics of finafloxacin in the murine thigh infection model with S. aureus and E. coli. Abstract. 50th ICAAC, Boston, MA.

30) Weiss, W. J., B. Hafkin, N. Kaplan, M. E. Pulse, P. Nguyen, P. Renick, J. Simecka. 2010. Oral pharmacokinetics and efficacy of AFN-1252 in a murine septicemia infection model with S. aureus. Abstract. 50th ICAAC, Boston, MA.

31) Pulse, M., P. Nguyen, J. Pierce, P. Renick, W. J. Weiss, J. Simecka. 2010. Efficacy of imipenem and tigecycline in a mouse pneumonia model infected with Acinetobacter baumannii. Abstract. 50th ICAAC, Boston, MA.

32) Pulse, M., W. Weiss, N. Reyes, C. Kostrub, P. Nguyen, P. Renick & J. Simecka. 2010. Efficacy of ACHN-490 in a Murine Urinary Tract Infection Model with Escherichia coli. Abstract #3254, 48th IDSA, Vancouver, Canada.

33) Pulse, M., P. Nguyen, J. Pierce, K. Peterson, D. Valtierra, W. J. Weiss, J. Simecka. 2011. Alpha-toxin neutralization significantly impacts Staphylococcus aureus biofilm formation. Abstract B-065. 51st ICAAC, Chicago, IL.

34) Pulse, M., N. Kaplan, J. parsons, C. Rock, D. Valtierra, W. J. Weiss. 2011. Effects of AFN-1252 on in viro and in vivoStaphylococcus aureus virulence gene expression. Abstract B-1763. 51st ICAAC, Chicago, IL.

35) Weiss, W. J., R. Vickers, M. Pulse, P. Nguyen, P. Renick, J. Simecka. 2011. Efficacy of SMT-19969 and SMT-21829 in a hamster model of Clostridium difficile disease. Abstract B-1195. 51st ICAAC, Chicago, IL.

36) Weiss, W. J., M. Pulse, P. Nguyen, J. Pierce, P. Renick, D. Valtierra, J. Simecka. 2011. Efficacy of Tigecycline and vancomycin in a rat Staphylococcus aureus endocarditis model. Abstract B-063. 51st ICAAC, Chicago, IL.

37) M. E. Pulse, N. Kaplan, J. Parsons, C. O. Rock, M. Kukula, P. Nguyen, J. Pierce, D. Valtierra, W. J. Weiss, J. W. Simecka. 2012. AFN-1252 Alters In Vitro and In Vivo Staphylococcus aureus Gene Expression and Reduces Bacterial Counts in a Mouse Granuloma Infection Model. 22nd ECCMID, London, UK.

38) W. J. Weiss, M. E. Pulse, P. Nguyen, J. Pierce, D. Valtierra, K. Peterson, J. Simecka & W. Stubbings. 2013. In vivo efficacy of the novel monosulfactam BAL30072 alone and in combination with meropenem against clinically important Gram-negative pathogens. 23rd ECCMID, Berlin, Germany.

39) M. E. Pulse, P. Nguyen, J. Peirce, K. Peterson, D. Valtierra, W. J. Weiss, B. Sellman, N. Ulbrandt, S. Krishnan, J. Suzich, W. Blair. 2013. Characterization of the programmed death 1 protein (PD-1) and its ligand (PD-L1) in a murine cecal ligation model of sepsis. 53rd ICAAC, Denver, CO.

40) M. E. Pulse, N. Kaplan, J. Parsons, C. O. Rock, M. Kukula, P. Nguyen, J. Pierce, D. Valtierra, W. J. Weiss, J. W. Simecka. 2012. AFN-1252 Alters In Vitro and In Vivo Staphylococcus aureus Gene Expression and Reduces Bacterial Counts in a Mouse Granuloma Infection Model. 22nd ECCMID, London, UK.

41) Weiss, W., M. Pulse, P. Nguyen, J. Pierce, D. Valtierra, K. Peterson, J. Simecka, M. page, W. Stubbings. 2013. In vivo Efficacy of the Novel Monosulfactam BAL30072 Alone and in Combination with Meropenem Against Clinically Important Gram-negative Pathogens. 23rd ECCMID, Berlin, Germany.

42) Pulse, M., P. Nguyen, K. Peterson, D. valtierra, W. Weiss, B. Sellman, N. Ulbrandt, S. Krishnan, J. Suzich, W. Blair. 2013. Characterization of the Programmed Death 1 Protein (PD-1) and its Ligand (PD-L1) in a Murine Cecal Ligation Model of Sepsis. Abstract B-1064. 53rd ICAAC, Denver, CO.

43) Miossec, C., S. Sayah-Jeanne, V. Augsutin, W. Weiss, M. Pulse, T. Murphy, A Andremont, J. Gunzburg. 2013. DAV131, An Oral adsorbent-based product, fully protects hamsters against moxifloxacin-induced Clostridium difficile lethal infection. Abstract F-631a. 53rd ICAAC, Denver, CO.

44) Pulse, T. Murphy, P. Nguyen, K. Peterson, J. Pierce, D. Valtierra, W. Weiss, S. Self. 2014. Ileal Dosing of a Nisin and Miconazole Combination is Efficacious in the Hamster Clostridium difficile Associated Disease Model. 24th ECCMID, Barcelona, Spain.

45) Miossec, C., S. Sayah-Jeanne, V. Augsutin, W. Weiss, M. Pulse, T. Murphy, A Andremont, J. Gunzburg. 2014. DAV131, an oral adsorbent-based product, exerts a dose-dependent protection of hamsters against moxifloxacin-induced Clostridium difficile lethal infection. 24th ECCMID, Barcelona, Spain

46) Weiss, W., T. Murphy, M. Pulse, J. Sutcliffe, T. Grossman. 2014. Pharmacodynamics of the Fluorocycline TP-271 in a Neutropenic Murine Lung Infection Model with Methicillin-resistant Staphylococcus aureus. 54th ICAAC, Washington, DC.

47) Murphy, T., W. Weiss, M. Pulse, J. Sutcliffe, T. Grossman. 2014. Pharmacodynamic evaluation of TP-271, a novel fluorocycline, in a neutropenic murine lung model infected with Streptococcus pneumoniae. 54th ICAAC, Washington, DC.

48) M. Pulse, M., T. M. Murphy, P. Nguyen, K. Peterson, J. M. Silva, D. Valtierra, J. Vitucci, W. J. Weiss, J. W. Simecka. 2014. Epidemic Clostridium difficile ribotype 027 stains are more virulent than other non-epidemic stains in the hamster CDAD model. 54th ICAAC, Washington, DC.

49) M. Pulse, T. Murphy, P. Nguyen, K. Peterson, J. Silva, J. Simecka, D. Valtierra, W. Weiss, S. Sayah-Jeanne, J. de Gunzburg. 2015. Evaluating the induction potential of three antibiotics in the hamster Clostridium difficile infection model. 25th ECCMID, Copenhagen, Denmark.

50) W. Weiss, T. Murphy, M. Pulse, P. Nguyen, D. Valtierra, K. Peterson, J. Silva, J. Simecka, J. Sutcliffe, T. Grossman. 2015. Efficacy evaluation of TP-271, a novel fluorocycline, in a neutropenic murine pneumonia model against susceptible and resistant gram-positive pathogens. . 25th ECCMID, Copenhagen, Denmark.

51) S. Ram, K. Menon, R. Scott, D. Weaver, K. Freeman, G. Tew, W. Weiss, W. DeGrado, K. Fadela, A. Kumar, D. Brennan, S. Holden. 2015. Synthetic novel host defense protein mime tics for the treatment of gram-negative bacterial infections. 25th ECCMID, Copenhagen, Denmark.

52) W. J. Weiss, M. Pulse, P. Nguyen, Z. Ma. 2016. In Vivo Efficacy of Dual-Action Molecule TNP-2092 in Mouse H. pylori Infection Model as Compared to Triple Therapies and Distribution within the Gastric Mucosal Layer. Microbe 2016, Boston, MA.

53) M. Pulse, W. J. Weiss, P. Nguyen, Z. Ma. 2016. In Vivo Efficacy of Dual-Action Molecule TNP-2092 in Mouse H. pylori Infection Model: Dose Relationship and Impact of Proton Pump Inhibitor. Microbe 2016, Boston, MA.

54) X. Xu, W. J. Weiss, G. T. Robertson, F. Guo4, C. Li, J. Zhang, L. Jiang, M. Yang, D. Xu, X. Wang, Z. Ma. 2016. In Vivo Efficacy of Dual-Action Molecule Tnp-2092 in Hamster and Mouse Clostridium difficile Infection Models. Microbe 2016, Boston, MA.

55) Saint-Lu, S. Sayah-Jeanne, F. Sablier-Gallis, M. Pulse, C. Burdet, T.T. Nguyen, W. Weiss, F. Mentré, E. Chachaty, Andremont and J. de Gunzburg. 2016. Extended protection by DAV131 against antibiotic-induced Clostridium difficile infection in hamsters. Microbe 2016, Boston, MA.

56) Charles Burdet, Thu Thuy Nguyen,, Nathalie Saint-Lu, Sakina Sayah-Jeanne, William Weiss, Mark Pulse, Antoine Andremont, France Mentré, Jean de Gunzburg. 2016. Modelling helps understanding reduction of mortality provided by DAV131A in a hamster model of moxifloxacin-induced Clostridium difficile colitis. ID Week, New Orleans, LA.

57) A Rubio, W Weiss, M Pulse, T Lister T R Parr Jr. 2017. In vivo Efficacy of Combinations of Novel Antimicrobial Peptide SPR741 and Rifampin in a K. pneumoniae Murine Model of Urinary Tract Infection. ASM Microbe 2017, New Orleans, LA

58) J. Newman, T. H. Grossman, M. E. Pulse, W. J. Weiss. 2017. The Novel Fluorocycline TP-271 is Efficacious in a Murine A. baumannii Pneumonia Model. ASM Microbe 2017, New Orleans, LA

59) J. Newman, M. E. Pulse, W. J. Weiss. 2017. PK/PD of the Novel Fluorocycline Eravacycline is Efficacious in a Murine E. coli Thigh Model. ASM Microbe 2017, New Orleans, LA

60) N. Saint-Lu, T. Corbel, F. Sablier-Gallis, M. Pulse, C. Burdet, Céline Wahl, T.T. Nguyen, W. Weiss, F. Mentré, S. Ferreira, A. Andremont3 and J. de Gunzburg. 2017. DAV131A prevents alterations of the intestinal microbiota and Clostridium difficile infection in hamsters treated with moxifloxacin and clindamycin. ASM Microbe 2017, New Orleans, LA

61) A. DeFusco, J. Ngoje, G. Phillips, M. Sivaram, J. Park, B. Tilley, E. Richeson, V. Sylva, Z. Lamon, F. Anazco, M. Pulse, W. J. Weiss, M. Handfield. 2017. Development of OG716, a Novel Lantibiotic Against Clostridium difficile. ASM Microbe 2017, New Orleans, LA.

62) W. J. Weiss, M. Pulse, P. Nguyen, T. R. Parr Jr, T. Lister and A. Rubio. 2017. Efficacy of Novel Cationic Peptide SPR741 and Gyrase Inhibitor SPR720 Combinations Against Carbapenem-resistant K. pneumoniae in a Murine UTI Model. M Microbe 2017, New Orleans, LA.

63) Weiss, W., M. Pulse, P. Nguyen, D. Valtierra, K. Peterson, K. Carter, D. Pevear, C. Burns, L. Xerri. 2018. Efficacy of Cefepime/ VNRX-5133, a Novel -lactamase Inhibitor, against a Cephalosporin-Resistant, ESBL-producing K. pneumoniae in a Murine Lung infection Model. 28th ECCMID, Madrid, Spain.

64) Pulse, M., W. Weiss, P. Nguyen, D. Valtierra, D. Pevear, C. Burns, L. Xerri. 2018. Efficacy of Cefepime / VNRX-5133, a Novel broad-spectrum -Lactamase Inhibitor, in a Murine Bacteremia Infection Model with Carbapenem Resistant Enterobacteriaceae (CREs). 28th ECCMID, Madrid, Spain

111) Weiss, W., M. Pulse, P. Nguyen, D. Valtierra, K. Peterson, K. Carter, D. Pevear, C. Burns, L. Xerri. 2018. Efficacy of Cefepime Combined with VNRX-5133, A Novel Broad-Spectrum β-Lactamase Inhibitor, against a Cephalosporin-Resistant ESBL E. coli in a Murine UTI Model. ASM Microbe 2018, Atlanta, GA.
65) Weiss, W., K. Carter, M. Pulse, P. Nguyen, D. Valtierra, K. Peterson, R. Tommasi, J. Mueller, J. O’Donnell. 2019. Efficacy of Cefpodoxime proxetil and ETX0282 in a murine UTI model with E. coli and K. pneumoniae. 29th ECCMID, Amsterdam, NE.

66) Hans-Jürgen, H., M. Pulse, W. Weiss, A. Lange, K. Gisch, Heike Kliem, M. Pfaffl, U. Kulozik, C. Von Eichel-Streiber. 2019. Concurrent treatment and prevention of recurrent Clostridium difficile infection with specific antibodies obtained from bovine milk in a hamster primary infection model. 29th ECCMID, Amsterdam, NE.

67) Olesky, M., J. Newman, J. Zhou, C. Fyfe, W. Weiss, M. Pulse. 2019. In vivo efficacy of TP-6076 in murine thigh and lung infection models challenged with Acinetobacter baumannii. 29th ECCMID, Amsterdam, NE.

68) Weiss, W, M. E. Pulse, P. Nguyen, D. Valtierra, K. Peterson, K. Carter, J. Weiss, T. Lodise, B. Tsuji, R. A. Bonomo. 2019. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam and Aztreonam in the Murine Thigh Infection Model. ASM Microbe 2019, San Francisco, CA

69) Weiss, W., K. Carter, J. Weiss, M. E. Pulse, E.J. Ellis-Grosse. 2019. In vitro and in vivo effects of Fosfomycin resistant mutants on bacterial growth and efficacy in the murine UTI model. ASM Microbe 2019, San Francisco, CA

70) Weiss, W, M. E. Pulse1, P. Nguyen, D. Valtierra1, K. Peterson, K. Carter, S. Yu, B. Cezairliyan, N. Sherden. 2019. Pathogenicity of Pseudomonas mutant strains and efficacy of aerosolized OTG005 in a murine lung infection model. ASM Microbe 2019, San Francisco, CA

71) Weiss, W, M. E. Pulse, P. Nguyen, D. Valtierra1, K. Peterson, K. Carter, J. Weiss, N. Mohapatra, D. Guenette. 2019. Efficacy of Novel Antimicrobial Compound in the Murine Thigh Infection Model with A.baumannii. ASM Microbe 2019, San Francisco, CA

72) Weiss,W, M. E. Pulse, P. Nguyen, D. Valtierra, K. Petersen, K. Carter, J. Weiss1, J. Zhou, J. Newman, J. DuMas. 2019. Pharmacokinetics and Efficacy of TP-6076 in the Murine Lung Infection Model with Acinetobacter baumannii. ASM Microbe 2019, San Francisco, CA

73) Pulse, M., W. Weiss, P. Nguyen, D. Valtierra, K. Petersen, K. Carter, J. Weiss1, J. Zhou, J. Newman, J. DuMas. 2019. Efficacy of TP-6076 in the Murine Thigh Infection Model with Acinetobacter baumannii. ASM Microbe 2019, San Francisco, CA

74) Pulse, M., W. Weiss, P. Nguyen, D. Valtierra, K. Peterson, K. Carter, G. Moeck, R. Trout, J. Hamrick, D. Pevear. 2019. Efficacy of ceftibuten + VNRX-7145 a novel β-lactamase inhibitor against ESBL E. coli strains in a Murine UTI Model. ASM Microbe 2019, San Francisco, CA

 

Invited Speaker

1)  W. Weiss. Pharmacokinetics and Pharmacodynamics in Drug Discovery.  Superbugs and Superdrugs. SMI Conference 2003, London, UK

2)  M. Pulse.  The Effects of Serine Protease-Like F (SplF) on Alpha-Toxin Expression in Staphylococcus aureus. Texas Wesleyan University, Department of Biology Student Research Presentations, April 2003.

3)  W. Weiss. Integrated platform to optimize agents for biofilm activity; Speaker and chairperson. Superbugs and Superdrugs. SMI Conference 2005, London, UK.

4)  W. Weiss. Device-related infections. Superbugs and Superdrugs. SMI Conference 2007, London, UK.

5)  W. Weiss. Gastro-intestinal Diseases. Superbugs and Superdrugs. SMI Conference 2008, London, UK.

6)  W. Weiss. Helicobacter pylori. Superbugs and Superdrugs. SMI Conference 2009. London, UK.

7)  W. Weiss. Anti-infective drug discovery through outsourcing and collaborations. Anti-Infective Summit 2010, Philadelphia, PA.

8)  W. Weiss. The role of academia in drug discovery and development. Anti-Infective Summit 2011. Philadelphia, PA.

9)  W. Weiss. Infectious disease drug discovery; how and where will the new antibiotics come from? SMI Conference 2011, London, UK.

10) W. Weiss. An Update on Current Issues and Progress in C. difficile Disease (CDAD). SMI Superbugs & Superdrugs – A Focus on Antibacterials, March 4-5, 2013, London, UK.

11) M. Pulse. Dosing clindamycin before or after infection dramatically impacts disease outcome in the hamster Clostridium difficile associated disease model. ICAAC 2013, Denver, CO.

12) W. Weiss. Research and Development in Neglected Diseases. SMI Superbugs & Superdrugs 2014. London, UK.

13) W. Weiss. The changing role of academia in drug discovery. SMI Superbugs andSuperdrugs 2015, London, UK.

14) W. Weiss. Combination Antimicrobial Therapy. SMI Conference Superbugs & Superdrugs 2016, London, UK.

15) W. Weiss. Combination Antimicrobial Therapy. Presenter and Chairman. SMI Conference Superbugs & Superdrugs USA 2016, Iselin, NJ.